Growth Metrics

Voyager Therapeutics (VYGR) Income towards Parent Company: 2014-2024

Historic Income towards Parent Company for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$65.0 million.

  • Voyager Therapeutics' Income towards Parent Company fell 208.40% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 589.88%. This contributed to the annual value of -$65.0 million for FY2024, which is 149.12% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Income towards Parent Company of -$65.0 million as of FY2024, which was down 149.12% from $132.3 million recorded in FY2023.
  • Voyager Therapeutics' Income towards Parent Company's 5-year high stood at $132.3 million during FY2023, with a 5-year trough of -$71.2 million in FY2021.
  • In the last 3 years, Voyager Therapeutics' Income towards Parent Company had a median value of -$46.4 million in 2022 and averaged $7.0 million.
  • Per our database at Business Quant, Voyager Therapeutics' Income towards Parent Company tumbled by 293.78% in 2021 and then skyrocketed by 385.14% in 2023.
  • Voyager Therapeutics' Income towards Parent Company (Yearly) stood at $36.7 million in 2020, then slumped by 293.78% to -$71.2 million in 2021, then spiked by 34.82% to -$46.4 million in 2022, then soared by 385.14% to $132.3 million in 2023, then crashed by 149.12% to -$65.0 million in 2024.